​

Elevation Oncology Stock (NASDAQ:ELEV)

ForecastOwnershipFinancialsChart
Elevation Oncology by TradingView

Previous Close

$0.37

52W Range

$0.22 - $3.09

50D Avg

$0.35

200D Avg

$0.49

Market Cap

$21.62M

Avg Vol (3M)

$1.35M

Beta

1.50

Div Yield

-

ELEV Company Profile

Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

34

IPO Date

Jun 25, 2021

Website

ELEV Performance

ELEV Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-44.70M$-45.45M$-94.55M
Net Income$-44.48M$-45.70M$-95.08M
EBITDA$-44.70M$-41.47M$-94.52M
Basic EPS$-0.78$-1.34$-4.09
Diluted EPS$-0.78$-1.34$-4.09

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
HTCRHeartCore Enterprises, Inc.
TCRXTScan Therapeutics, Inc.
OCEAOcean Biomedical, Inc.
TECXTectonic Therapeutic, Inc.
INABIN8bio, Inc.
UNCYUnicycive Therapeutics, Inc.
ENVBEnveric Biosciences, Inc.